<?xml version="1.0" encoding="UTF-8"?>
<p>Nearly half of patients with mCRC responded well to IRI (aCRCS A1 + B1, 46.8%), while only about 20% responded well to OX (aCRCS B2, 18.5%). Therefore, the PFS of IRI‐based therapy was consistently better compared with OX‐based therapy, although the difference was not statistically significant.
 <xref rid="cas14841-bib-0003" ref-type="ref">
  <sup>3</sup>
 </xref>, 
 <xref rid="cas14841-bib-0004" ref-type="ref">
  <sup>4</sup>
 </xref>, 
 <xref rid="cas14841-bib-0006" ref-type="ref">
  <sup>6</sup>
 </xref>
</p>
